How CCRM Australia’s academic and industry partnerships helped an industry innovator connect with academic expertise and resources to deliver commercial-scale cell manufacturing. About Cynata Cynata is an Australian
Regenerative medicine is a risky business. The decades-long development pipeline and the expenditure of millions of dollars presents itself as an insurmountable mountain for many researchers. The regenerative
CCRM Australia has been helping early career researchers and high-achieving PhD candidates to gain the skills needed to commercialise and translate their regenerative medicine research into thriving business
Innovative and curative treatments continually push the boundaries of treating known medical conditions. However, as the world changes gears, shifting from small molecules to cellular and gene therapies,
The Centre for Commercialization of Regenerative Medicine Australia and BioCurate enter into a Memorandum of Understanding (MoU) to accelerate the translation of therapies in the Australian regenerative medicine
Innovative and curative treatments push the limits of the government’s finite reimbursement purse. This pressing issue brings to light the growing concerns surrounding the reimbursement of cell therapies
It was a sunny Philadelphia that greeted the 11th Business of Regenerative Medicine Symposium. Hosted at the University of Pennsylvania’s Similow Center for Translational Research, the two-day symposium
Nerve (neuropathic) pain affects one in twenty Australians. For some, it’s a frustration, for others it’s nothing short of debilitating. What’s worse, nerve damage often cannot be entirely
In 2008, mesenchymal stem cells were not gracing the front page of prestigious academic journals as they do today. Yet the founders of Regeneus knew differently. A company
As stem cell therapies move through clinical trials and get closer to the clinic, they are giving rise to new challenges, primarily around costs and the likelihood of
